Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens

Hu-Dachuan Jianga School of Public Health, Southeast University, Nanjing, People’s Republic of ChinaView further author information

Xi-ling Guob NHC Key laboratory of Enteric Pathogenic Microbiology(Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, People’s Republic of ChinaView further author information

Peng-Fei Jinb NHC Key laboratory of Enteric Pathogenic Microbiology(Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, People’s Republic of ChinaView further author information

Rong Tangb NHC Key laboratory of Enteric Pathogenic Microbiology(Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, People’s Republic of ChinaView further author information

Jing-Xin Lib NHC Key laboratory of Enteric Pathogenic Microbiology(Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, People’s Republic of ChinaCorrespondence[email protected]
View further author information

Feng-Cai Zhua School of Public Health, Southeast University, Nanjing, People’s Republic of China;b NHC Key laboratory of Enteric Pathogenic Microbiology(Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, People’s Republic of ChinaCorrespondence[email protected]

https://orcid.org/0000-0002-1644-0006 View further author information

References

COVID-19 vaccine tracker. VIPER Group COVID19 Vaccine Tracker Team. 2022 Apri). https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list.
Google Scholar
Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85.
PubMed Web of Science ®Google Scholar
Price AM, Olson SM, Newhams MM, et al. BNT162b2 protection against the Omicron variant in children and adolescents. N Engl J Med. 2022;386(20):1899–1909.
PubMed Web of Science ®Google Scholar
Ai J, Zhang H, Zhang Q, et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern. Cell Res. 2022;32(1):103–106.
PubMed Web of Science ®Google Scholar
Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 2022;399(10324):521–529.
PubMed Web of Science ®Google Scholar
Li J, Hou L, Guo X, et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28(2):401–409.
PubMed Web of Science ®Google Scholar

Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date